Physician profile
Peter J Macander
NPI 1285613851
$911.47
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $17.12 · 2022: $58.46.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $241.64 | 2019 | |
| Cardiovascular Systems INC. | $153.85 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $114.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $95.01 | 2019-2022 | |
| Biotronik INC. | $90.72 | 2019 | |
| Janssen Pharmaceuticals, INC | $66.29 | 2019-2020 | |
| Amgen INC. | $39.83 | 2019 | |
| Pfizer INC. | $35.47 | 2019 | |
| Philips North America LLC | $21.77 | 2019 | |
| Amarin Pharma, INC. | $18.97 | 2019 | |
| Irhythm Technologies, INC. | $17.32 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.47 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Macander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.